Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Medtech Insight

Generics Bulletin

Market Forces May Impact GDUFA III Talks

Mar 28 2019

• By Derrick Gingery

FDABldg1ExteriorWithCircle_1200x675

Related Content

FDA Contradicts AAM's Generic Market Consolidation Argument

Nov 21 2017

Unhappy With GDUFA II? Note It For GDUFA III, FDA Says

Nov 28 2017

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Aug 28 2017

Biosimilars At US FDA: Personnel Spending Losing Influence Over Program

Aug 19 2018

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

May 04 2018

Will GDUFA III Curtail Priority Assessments?

Sep 14 2018

BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process

Oct 22 2018

Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity

Mar 12 2019

CREATES Act: Republican Lawmakers Worry About Frivolous Lawsuits By Generic Firms

Mar 13 2019

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Mar 07 2019

Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics

Mar 07 2019

Related Companies

Pfizer Inc.

Johnson & Johnson

Additional Topics

United States Generic Drugs FDA Regulation Biosimilars BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
Editorial Standards
Award-Winning Journalism
AdvertiseOpens in new window
Contact Us
Evaluate Home

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window